Syntimmune Inc

Alexion Pharmaceuticals is engaged in the discovery and development of therapeutic products aimed at treating patients with an array of diseases, including hematologic and cardiovascular disorders, autoimmune diseases and cancer. Alexion's two primary product candidates, pexelizumab and eculizumab, are currently undergoing evaluation in several clinical development programs with the Federal Drug Administration. Alexion is engaged in discovering and developing a pipeline of additional antibody therapeutics targeting severe unmet medical needs, through its wholly owned subsidiary, Alexion Antibody Technologies. During the fiscal year ended July 31, 2005, eculizumab was in Phase III clinical development for treatment of paroxysmal nocturnal hemoglobinuria , a chronic hematologic disease, and pexelizumab was in clinical development for two acute cardiac indications. Alexion is also pursuing additional potential indications for eculizumab and has other product candidates in earlier stages of development. Alexion Pharmaceuticals is based in Cheshire, Conn.

Radius Health, Inc. is a biopharmaceutical company based in Boston, MA, focused on transforming the future of bone health for underserved patient populations. With a commitment to innovation, the company prioritizes patient well-being, evidenced by the launch of its first commercial product, TYMLOS, and subsequent expansions in its portfolio. Rooted in a culture of agility and integrity, Radius emphasizes a collaborative environment where employees are encouraged to bring their best to their work. The leadership team, comprised of experienced professionals from various sectors of the pharmaceutical industry, is dedicated to advancing the company's mission and enhancing the lives of patients. Generated from the website

From the website:Foundation Medicine is a world-leading molecular insights company, connecting physicians, patients and biopharma partners to the latest insights in cancer genomics. Learn more.